Atomwise vs Abridge

Abridge has a disclosed valuation of $5.3B, while Atomwise's valuation is not publicly available, making a direct size comparison difficult. Abridge employs 120 people.

Abridge has raised more in total funding at $800M, compared to Atomwise's $219M — a gap of $581M. Combined, the two companies have completed 7 known funding rounds.

Abridge leads with an Awaira Score of 76/100, while Atomwise sits at 53/100. That 23-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Atomwise was founded by Abraham Heifets in 2012. Abridge was founded by Shiv Rao in 2018. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform applies machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology uses natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence.

Atomwise got there first, launching in 2012 — that's 6 years of extra runway. Abridge didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Atomwise has about 75 employees; Abridge has about 120. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Atomwise and Abridge compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.